NON-HODGKIN'S LYMPHOMA

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This early-phase study tests a new treatment for people with certain blood cancers (lymphoma or leukemia) that have returned after a stem cell transplant. Researchers take immune cells (T cells) from the original stem cell donor, modify them to recognize and attack cancer cells c…

This early-phase study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 is a type of immune cell therapy (CAR T) made from donor cells, designed to target cancer cells. The main goal is to chec…

This early-phase study tested whether giving patients their own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for treating aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Se…

This study tests whether giving palifermin and leuprolide acetate (or degarelix) can help the immune system recover more quickly after a stem cell transplant from a donor. The trial includes 82 adults with blood cancers like leukemia or lymphoma. Researchers will measure CD4+ T c…

This study tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma, a type of blood cancer, in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over several months. The goal is to see how many achieve a…

This study is testing a new drug called glofitamab, alone or with another drug (obinutuzumab), in about 940 people whose B-cell non-Hodgkin's lymphoma has come back or stopped responding to standard treatments. The goal is to find the safest and most effective dose and see how we…

This early-phase study tests a new way to fight Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein on lymphoma cells, and also tra…

This early-phase study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to check safety and find the best dose. About 78 adults will take the drug by mouth at different dose levels over up to 64 months.

This study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…

This study collects white blood cells from people with leukemia or lymphoma whose cancer has not been cured by standard treatments. The cells are stored and may later be used to create a personalized therapy called CAR T-cells. The goal is to make it easier for patients to get th…

This early-phase study is testing a tiny amount of a new drug called 124I-PUH71 in 63 people with certain cancers (lymphoma, myeloma, or solid tumors). The goal is not to treat the cancer, but to see how the drug spreads through the body and collects in tumors, and how long it st…